Flurbiprofen
Arthropathy
Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Express Specialty Pharmacy
Modality
Small molecule
Development Phase
Unknown
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02403687CT.gov Prospective Analgesic Compound Efficacy (PACE) Study | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Arthropathy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Flurbiprofen (this asset) | Express Specialty Pharmacy | Unk | D · 30 |
| Diclofenac | Express Specialty Pharmacy | P4 | BBB |
| Propofol | Pedro Paulo Tanaka | P4 | BB |
| Desflurane | Pedro Paulo Tanaka | P4 | BB |
| Testosterone Undecylate | Alliance for Clinical Trials in Oncology | P3 | BB |
| Letrozole | ARKAY Therapeutics | P2 | BB |
| Gabapentin | British Columbia Cancer Agency | P2/3 | B |
| Calcarea Gluconica | University of Washington | P2 | B |
| Autologous Conditioned Plasma | Rehasport Clinic | P2 | CCC |
+24 more in the Arthropathy cohort
Other indications for Flurbiprofen
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Sickle Cell Disease | — | P1 | CC · 40 |
| Tendinitis | — | Unk | D · 30 |
| Chronic Pain Syndrome | — | N/A | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Flurbiprofen in Arthropathy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/flurbiprofen-arthropathy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →